CFTR modulators and biologics have had a significant impact on the treatment of cystic fibrosis and severe asthma in recent years. Despite all the benefits that these active substances bring, some patients can also experience significant side effects. Some extrapulmonary consequences still receive too little attention in practice.
Autoren
- Jens Dehn
Publikation
- InFo PNEUMOLOGIE & ALLERGOLOGIE
Related Topics
You May Also Like
- Treatment of type 2 diabetes: paradigm shift continues
Cardiorenal organ protection is increasingly coming to the fore
- Semaglutide and tirzepatide in HFpEF and T2D/obesity
Prospect of improved cardiovascular prognosis
- Case report: alveolar sarcoidosis
Acute hypoxemic respiratory failure as initial manifestation
- "Swiss Health Care Atlas"
Supply situation in Switzerland: Update
- Adrenogenital syndrome
Clinical care from birth to adulthood
- Lung cancer
Multidisciplinary teams in oncology
- Psoriasis: System therapies in everyday practice
Current real-world data at a glance
- Omega-3 fatty acids for obesity and type 2 diabetes